Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28371227 | 0.82 | MEN1 (0.41) | SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL8938553 | 0.77 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3GRM2 | |
| SCHEMBL30932325 | 0.75 | DDB1 (0.37) | SLC6A2SLC6A4SLC6A3GRM2MAOB | |
| SCHEMBL6196561 | 0.75 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL16757473 | 0.75 | CHRM2 (0.46) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL7830549 | 0.75 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL9781650 | 0.72 | HTT (0.49) | SLC6A2SLC6A4SLC6A3GRM2 | |
| SCHEMBL9639599 | 0.69 | BCHE (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL873444 | 0.68 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 | |
| SCHEMBL51254 | 0.68 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3GRM2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-6914160-B1 | Oxytocin inhibitors | PFIZER INC (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1537085-A1 | OXYTOCIN INHIBITORS | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020414-A1 | OXYTOCIN INHIBITORS | PFIZER LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
| EP-1104407-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2001000586-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | SLC6A2 4758/4885SLC6A4 4747/4885SLC6A3 4653/4885 |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | SLC6A2 436/4885SLC6A4 725/4885SLC6A3 709/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | SLC6A2 4845/4885SLC6A4 4849/4885SLC6A3 4842/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | SLC6A2 4845/4885SLC6A4 4849/4885SLC6A3 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.